Hair Loss: When to See a Doctor and What's Actually Causing It

How Much Hair Loss Is Actually Normal?

The average scalp holds roughly 100,000 hair follicles, and each follicle cycles through growth (anagen), transition (catagen), and rest (telogen) phases independently. At any given moment, about 10 to 15 percent of follicles sit in the telogen phase and shed naturally. That translates to 50 to 100 hairs per day, which is physiologically normal and not a reason for concern.

The American Academy of Dermatology defines clinically significant hair loss as shedding that exceeds this range, produces visible thinning, or results in discrete bald patches. [1]

The Pull Test

A simple bedside test gives you a quick read. Grasp a small bundle of roughly 60 hairs between thumb and forefinger, apply gentle traction, and count the hairs that come free. Pulling out more than six hairs in a single pass suggests active effluvium and is worth documenting before a clinic appointment.

What Changes in the Shower Count

Count hairs on your pillow or in the shower drain for five consecutive mornings. Consistently finding clumps larger than a quarter coin diameter is a signal the daily loss rate has climbed above normal. This simple tally gives your clinician objective data rather than a vague complaint.

When Should You Actually Worry About Hair Loss?

See a clinician within two to four weeks if you notice any of the following. Rapid onset bald patches, patches with broken hairs at the margin, scalp tenderness, burning, or visible scarring all require evaluation sooner rather than later. Some causes are irreversible if left untreated beyond a certain window.

Red-Flag Signs That Need Prompt Evaluation

• Circular or oval bald patches appearing within days to weeks (possible alopecia areata)
• Diffuse shedding starting four to twelve weeks after a major illness, surgery, COVID-19 infection, or childbirth (telogen effluvium)
• Hairline recession combined with scalp scaling, redness, or pustules (possible fungal infection or lichen planopilaris)
• Hair loss that began within six weeks of starting a new prescription medication
• Eyebrow or eyelash loss alongside scalp hair loss (raises concern for alopecia universalis or thyroid disease)

Scarring vs. Non-Scarring Alopecia

The single most important distinction a dermatologist makes is whether the hair follicle is scarred. Non-scarring alopecias (androgenetic alopecia, telogen effluvium, alopecia areata) are potentially reversible. Scarring alopecias, such as lichen planopilaris or central centrifugal cicatricial alopecia (CCCA), permanently destroy follicles. Waiting months before evaluation may reduce the treatable surface area significantly.

The North American Hair Research Society notes that early biopsy in suspected scarring alopecia directly changes treatment decisions and should not be deferred. [2]

What Causes Hair Loss?

Hair loss has more than 50 documented causes. The five most common account for the large majority of cases seen in primary care and dermatology offices.

Androgenetic Alopecia (Pattern Hair Loss)

Androgenetic alopecia (AGA) is the most prevalent form in both sexes. In men it follows the Norwood-Hamilton scale, receding at the temples and vertex. In women it typically produces diffuse thinning over the crown while the frontal hairline stays intact (Ludwig classification).

Dihydrotestosterone (DHT), converted from testosterone by 5-alpha-reductase type II, miniaturizes genetically susceptible follicles over years. Approximately 50% of men show AGA by age 50, and that figure rises to 80% by age 70. [3] Up to 40% of women experience female-pattern hair loss (FPHL) by age 70, though hormonal fluctuations around menopause accelerate onset in many. [4]

Telogen Effluvium

Telogen effluvium (TE) is the second most common cause. A systemic stressor pushes a large cohort of anagen follicles simultaneously into telogen; two to four months later, those follicles shed en masse.

Common triggers include:

• Major surgery or hospitalization
• COVID-19 infection (a 2021 systematic review found hair loss in up to 25% of COVID-19 survivors at three months) [5]
• Rapid caloric restriction or weight loss exceeding 1 kg per week
• Childbirth (postpartum effluvium typically peaks at three months postpartum)
• Iron deficiency, with serum ferritin below 30 ng/mL as the threshold most often cited in dermatology literature [6]

TE is self-limiting in most cases. If the trigger is removed, regrowth proceeds over six to twelve months.

Alopecia Areata

Alopecia areata (AA) is an autoimmune condition in which T-cells attack the hair follicle bulb. It affects roughly 2% of the global population across a lifetime. [7] Presentation ranges from single coin-sized patches to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis).

A landmark 2023 trial, the BRAVE-AA1 and BRAVE-AA2 studies (combined N=1,200), showed that baricitinib 4 mg daily produced a SALT (Severity of Alopecia Tool) score of 20 or less (meaning at least 80% scalp coverage) in 38.8% of patients at 36 weeks versus 6.2% on placebo. [8] The FDA approved baricitinib for severe AA in June 2022, the first systemic drug approved specifically for this indication.

Thyroid and Hormonal Causes

Both hypothyroidism and hyperthyroidism disrupt the hair cycle. The hair loss in thyroid disease tends to be diffuse, affecting the whole scalp rather than following a pattern. A TSH outside the reference range of approximately 0.4 to 4.0 mIU/L is a mandatory first blood test in any patient presenting with unexplained diffuse shedding.

Elevated androgens from polycystic ovarian syndrome (PCOS) or adrenal disorders drive FPHL in younger women. A 2020 review in the Journal of the American Academy of Dermatology found that up to 67% of women with FPHL who are under age 35 had at least one biochemical androgen abnormality on laboratory workup. [9]

Nutritional and Medication Causes

Iron deficiency is the most correctable nutritional trigger. Zinc deficiency, biotin deficiency (rare outside total parenteral nutrition patients), and protein malnutrition all appear in the literature as reversible causes.

Medications associated with hair loss include:

• Anticoagulants (warfarin, heparin, newer oral anticoagulants)
• Retinoids (isotretinoin, acitretin)
• Beta-blockers
• Lithium
• Chemotherapy agents (typically causing anagen effluvium)
• High-dose thyroid replacement exceeding physiological need
• Rarely, GLP-1 receptor agonists at doses producing very rapid weight loss (likely secondary TE from caloric deficit rather than direct drug toxicity)

How Is Hair Loss Diagnosed?

Diagnosis starts with a structured history and physical exam, not a battery of expensive tests.

Clinical History

Your clinician will ask about onset speed, distribution pattern, associated symptoms (scalp itch, burning, pain), recent illnesses, weight changes, new medications, family history of hair loss, and for women, menstrual history and recent pregnancies.

Physical Examination

Dermoscopy (trichoscopy) has transformed the non-invasive evaluation of hair loss. A 2019 consensus review in the International Journal of Dermatology found trichoscopy has a diagnostic accuracy above 90% for distinguishing AGA from AA and scarring alopecias when performed by trained clinicians. [10]

The clinician looks at follicular unit density, miniaturized versus terminal hair ratios, perifollicular signs, and scalp surface features.

Laboratory Tests

Standard first-line labs for unexplained hair loss:

| Test | What It Screens For | |---|---| | TSH | Thyroid dysfunction | | Serum ferritin | Iron deficiency | | CBC with differential | Anemia, chronic disease | | Free testosterone, DHEA-S | Hyperandrogenism (women) | | Zinc | Nutritional deficiency | | Prolactin | Hyperprolactinemia |

A scalp biopsy, typically 4 mm punch biopsy, is reserved for cases where trichoscopy and labs do not yield a diagnosis, or when scarring alopecia is suspected. Horizontal sectioning of the biopsy specimen allows follicular unit counting and provides the most diagnostic information.

What Treatments Are Available?

Treatment depends entirely on cause. Applying minoxidil to a ferritin-deficient patient without correcting iron status produces inferior results. Sequence matters.

Topical Minoxidil

Minoxidil is a potassium-channel opener that prolongs the anagen phase. At 2%, it is FDA-approved for women; at 5%, it is approved for men, though many dermatologists prescribe 5% off-label for women who fail 2%.

A Cochrane review of 27 randomized controlled trials found that 5% minoxidil solution produced significantly greater hair regrowth than 2% minoxidil solution in men with AGA, with a relative risk of having at least moderate regrowth of 1.34 (95% CI 1.11 to 1.62). [11]

A once-daily oral minoxidil formulation at 0.25 to 5 mg gained traction after a 2020 placebo-controlled trial (N=90) showed mean hair density increased by 12.0 hairs per cm² at 24 weeks. [12]

Finasteride and Dutasteride

Finasteride 1 mg/day inhibits 5-alpha-reductase type II, reducing scalp DHT by approximately 60%. A two-year randomized trial (N=1,553) published in the Journal of the American Academy of Dermatology found that finasteride halted progression in 86% of men and produced visible regrowth in 65% versus 7% on placebo. [13]

Dutasteride 0.5 mg/day inhibits both type I and type II 5-alpha-reductase, reducing serum DHT by approximately 90%. A meta-analysis of six RCTs found dutasteride superior to finasteride for hair count outcomes, though its use for AGA remains off-label in the United States. [14]

Women of childbearing potential must not use finasteride or dutasteride due to risk of fetal genital anomalies.

JAK Inhibitors for Alopecia Areata

Beyond baricitinib, the FDA approved ritlecitinib 50 mg/day in June 2023 for severe AA in patients 12 years and older, based on the ALLEGRO Phase 2b/3 trial (N=718). At 24 weeks, 23% of ritlecitinib-treated patients achieved a SALT score of 20 or below, versus 1.6% on placebo (P<0.001). [15]

Ruxolitinib cream 1.5% received FDA approval for mild-to-moderate AA in 2023, providing a topical JAK inhibitor option for patients who prefer to avoid systemic therapy.

Low-Level Laser Therapy (LLLT)

LLLT devices (combs, helmets, caps) delivering 650 to 670 nm wavelength light show modest but statistically significant hair density improvements in AGA. A meta-analysis of eleven RCTs (N=680) found a mean increase of 17.2 hairs per cm² versus sham devices. [16] Devices cleared by the FDA as 510(k) medical devices include the iGrow and HairMax LaserBand. Results require ongoing use and diminish after cessation.

Platelet-Rich Plasma (PRP)

PRP involves drawing the patient's blood, centrifuging to concentrate growth factors, and injecting into the scalp. A 2019 meta-analysis of twelve controlled studies found mean hair density increased by 45.9 hairs per cm² at three months in AGA patients. [17] PRP is not FDA-approved for hair loss but is widely offered as an adjunct. The evidence base is limited by small sample sizes and variable preparation protocols.

HealthRX Clinical Decision Framework: Matching Treatment to Cause

| Hair Loss Type | First-Line Option | Add-On if Inadequate Response at 6 Months | |---|---|---| | Male AGA (Norwood I-III) | Topical minoxidil 5% | Finasteride 1 mg/day oral | | Male AGA (Norwood IV+) | Finasteride 1 mg/day + topical minoxidil 5% | Dutasteride 0.5 mg/day (off-label) or PRP series | | Female FPHL (premenopausal) | Topical minoxidil 2 to 5% | Spironolactone 100 to 200 mg/day (off-label) | | Female FPHL (postmenopausal) | Topical minoxidil 5% | Oral minoxidil 0.25 to 1.25 mg + hormone evaluation | | Telogen effluvium | Identify and correct trigger (iron, thyroid, nutrition) | Topical minoxidil for supportive coverage if prolonged | | Alopecia areata (severe) | Baricitinib 4 mg/day or ritlecitinib 50 mg/day | Combination with topical minoxidil 5% | | Scarring alopecia | Dermatology referral for biopsy; hydroxychloroquine or topical calcineurin inhibitors per type | Hair transplant only after documented disease quiescence for 2+ years |

Hair Loss in Special Populations

Hair Loss After GLP-1 Therapy or Bariatric Surgery

Rapid weight loss, whether from semaglutide (Ozempic, Wegovy), tirzepatide (Zepbound), or surgical intervention, is a well-documented trigger for telogen effluvium. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced mean weight loss of 14.9% at 68 weeks. [18] Among participants losing weight rapidly in the first 12 to 20 weeks, self-reported hair loss was among the most noted non-GI adverse events.

The mechanism is almost certainly caloric and protein deficit rather than a direct drug effect. Maintaining protein intake above 1.2 g/kg of ideal body weight per day and ensuring ferritin stays above 40 ng/mL may reduce the severity of effluvium during active weight loss.

Postpartum Hair Loss

Estrogen levels plummet within 24 to 48 hours of delivery. The high-estrogen state of pregnancy had kept an unusually large percentage of follicles in anagen. The crash triggers a synchronized shift to telogen, and shedding peaks at three months postpartum.

Reassure patients this is transient. Greater than 95% of women see full recovery by 12 months without any treatment. If shedding persists past 12 months, evaluation for thyroid dysfunction and iron deficiency is indicated.

Hair Loss in Transgender Patients on Hormone Therapy

Testosterone therapy in transgender men can trigger or accelerate AGA in those with genetic susceptibility, typically within the first six to twenty-four months of therapy. Topical minoxidil 5% can be started prophylactically in patients with a strong family history of pattern hair loss.

Transgender women on estrogen therapy may see partial reversal of AGA, but the timeline varies and regrowth is generally incomplete without adjunct finasteride or minoxidil.

How to Prepare for Your Hair Loss Appointment

Bring the following to maximize diagnostic yield in a single visit:

1. A six-month photo diary (front, top, and sides) taken in the same lighting each week.
2. A list of all current medications, supplements, and hormonal therapies, including start dates.
3. Any recent blood work, especially CBC, TSH, and iron studies.
4. A timeline of major physical stressors: illnesses, surgeries, weight changes, dietary changes, and life stress events.

Dr. Antonella Tosti, a dermatologist and hair disorder specialist at the University of Miami, has stated: "The history alone directs diagnosis in the majority of hair loss cases. High-quality clinical photographs taken by the patient over months are often more informative than a cross-sectional scalp exam in the office." [19]